IL254115A0 - Crystalline forms of a pyrrolpyridine compound - Google Patents

Crystalline forms of a pyrrolpyridine compound

Info

Publication number
IL254115A0
IL254115A0 IL254115A IL25411517A IL254115A0 IL 254115 A0 IL254115 A0 IL 254115A0 IL 254115 A IL254115 A IL 254115A IL 25411517 A IL25411517 A IL 25411517A IL 254115 A0 IL254115 A0 IL 254115A0
Authority
IL
Israel
Prior art keywords
crystalline forms
pyrrolopyridine compound
pyrrolopyridine
compound
crystalline
Prior art date
Application number
IL254115A
Other languages
English (en)
Hebrew (he)
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55521844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL254115(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Publication of IL254115A0 publication Critical patent/IL254115A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL254115A 2015-02-26 2017-08-23 Crystalline forms of a pyrrolpyridine compound IL254115A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562121396P 2015-02-26 2015-02-26
PCT/US2016/019904 WO2016138458A1 (en) 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound

Publications (1)

Publication Number Publication Date
IL254115A0 true IL254115A0 (en) 2017-10-31

Family

ID=55521844

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254115A IL254115A0 (en) 2015-02-26 2017-08-23 Crystalline forms of a pyrrolpyridine compound

Country Status (21)

Country Link
US (2) US20160251350A1 (https=)
EP (1) EP3262042A1 (https=)
JP (1) JP2018506562A (https=)
KR (1) KR20170118762A (https=)
CN (1) CN107406447A (https=)
AR (1) AR103801A1 (https=)
AU (1) AU2016225070A1 (https=)
BR (1) BR112017018230A2 (https=)
CA (1) CA2976665A1 (https=)
CL (1) CL2017002180A1 (https=)
CO (1) CO2017009662A2 (https=)
CR (1) CR20170439A (https=)
HK (1) HK1246786A1 (https=)
IL (1) IL254115A0 (https=)
MA (1) MA41599A (https=)
MX (1) MX2017010888A (https=)
PE (1) PE20171327A1 (https=)
PH (1) PH12017501532A1 (https=)
RU (1) RU2017133093A (https=)
SG (1) SG11201706824TA (https=)
WO (1) WO2016138458A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115385871A (zh) * 2019-01-29 2022-11-25 沪亚生物国际有限公司 舒欣啶盐
EP3923948A4 (en) * 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
ES2621857T3 (es) * 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
KR102325163B1 (ko) * 2013-08-22 2021-11-11 제넨테크, 인크. 화합물의 제조 방법
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds

Also Published As

Publication number Publication date
CL2017002180A1 (es) 2018-03-16
KR20170118762A (ko) 2017-10-25
HK1246786A1 (zh) 2018-09-14
PE20171327A1 (es) 2017-09-12
WO2016138458A1 (en) 2016-09-01
AR103801A1 (es) 2017-06-07
SG11201706824TA (en) 2017-09-28
PH12017501532A1 (en) 2018-02-05
MA41599A (fr) 2018-01-02
AU2016225070A1 (en) 2017-09-07
US20160251350A1 (en) 2016-09-01
US20180282324A1 (en) 2018-10-04
BR112017018230A2 (pt) 2018-04-17
JP2018506562A (ja) 2018-03-08
EP3262042A1 (en) 2018-01-03
CR20170439A (es) 2018-01-08
MX2017010888A (es) 2017-12-15
RU2017133093A (ru) 2019-03-26
CN107406447A (zh) 2017-11-28
CO2017009662A2 (es) 2018-02-28
RU2017133093A3 (https=) 2019-08-23
CA2976665A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
IL263429A (en) Crystalline forms of a triazolopyrimidine compound
IL252843A0 (en) A process for preparing a diarylthiohydantoin compound
IL281292B1 (en) Processes for preparing a diarylthiohydantoin compound
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
SG10201911417PA (en) Crystalline compounds
IL254530A0 (en) Preparation method of crystalline form a of pci-32765
GB201522771D0 (en) Crystalline form of a phosphate derivative
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
PL3529236T3 (pl) Krystaliczne formy erawacykliny
IL253479A0 (en) Crystalline forms of efinconazole
ZA201606653B (en) Solid forms of a pharmaceutically active compound
IL259982A (en) Crystalline forms of thienopyrimidine compound
IL254115A0 (en) Crystalline forms of a pyrrolpyridine compound
ZA201607107B (en) Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound
IL259981A (en) Crystalline forms of hydrochloride salts of thienopyrimidine compound
GB201604759D0 (en) Crystalline compounds
GB201704789D0 (en) Crystalline compounds